Study of Nasal Insulin to Fight Forgetfulness - Long-acting Insulin Detemir - 120 Days (SL120)
Status:
Completed
Trial end date:
2015-03-12
Target enrollment:
Participant gender:
Summary
The study will examine the effects of intranasally administered long-acting insulin detemir
on cognition in persons with Alzheimer's disease (AD) or amnestic mild cognitive impairment
(aMCI). The rationale for these studies is derived from growing evidence that insulin
contributes to multiple brain functions, and that insulin dysregulation can contribute to AD
pathogenesis. Thus, therapies aimed at restoring normal insulin signaling in the CNS may have
beneficial effects on brain function. Intranasal administration of insulin increases insulin
signaling in the brain without raising peripheral levels and causing hypoglycemia. Insulin
detemir is an insulin analogue that may have better action in brain than other insulin
formulations because of its albumin binding properties. The investigators will test the
therapeutic effects of intranasally-administered insulin detemir in a study in which
participants will receive insulin detemir, regular insulin, or placebo over a four month
period. The investigators will test the hypothesis that insulin and insulin detemir will both
improve memory and daily functioning in persons with AD/aMCI compared with placebo, but that
insulin detemir will have the greatest effect.